Immunotherapy in Lung Cancer
Immunotherapy in Lung Cancer
复制标题
DOI：
10.1016/j.hoc.2016.08.004
复制
发表时间：
2017-02-01
影响因子：
2.4
通讯作者：
Morgensztern, Daniel
中科院分区：
文献类型：
--
作者：
Du, Lingling;Herbst, Roy S.;Morgensztern, Daniel
表现状态良好的晚期非小细胞肺癌患者的治疗一直以一线铂基双药和二线多西他赛的使用为基础。免疫疗法代表了一种新的治疗方法，具有长期受益的潜力。尽管所研究的疫苗并未显示出对非小细胞肺癌患者的益处，但在随机临床试验中，针对PD-1/PD-L1轴的免疫检查点抑制剂显示，与多西紫杉醇相比，总生存期增加，这导致了纳沃单抗和派姆单抗的批准。由于只有少数患者能从这类药物中受益，因此人们一直在积极寻找生物标志物。
The treatment of patients with good performance status and advanced stage non-small cell lung cancer has been based on the use of first-line platinum-based doublet and second-line docetaxel. Immunotherapy represents a new therapeutic approach with the potential for prolonged benefit. Although the vaccines studied have not shown benefit in patients with non-small cell lung cancer, immune checkpoint inhibitors against the PD-1/PD-L1 axis showed increased overall survival compared with docetaxel in randomized clinical trials, which led to the approval of nivolumab and pembrolizumab. Because only a minority of patients benefit from this class of drugs, there has been an intense search for biomarkers.